MEOPA-coupled Hypnosis Versus MEOPA-standard Care in Transesophageal Echocardiography

Cardiac Diseases Clinical Trial

— HYPNETO  

Official title:

Randomized Trial Comparing the Use of MEOPA (Equimolar Mixture of Nitrogen Protoxide and Oxygen)-Coupled Hypnosis Versus MEOPA Standard Care of Pain and Anxiety During Transesophageal Echocardiography (TEE) in Conscious Patients.

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04398017
• Other study ID #: 7351
• Status: Terminated
• Phase: N/A
• Start date: October 14, 2020
• Est. completion date: August 12, 2022

Study information

• Verified date: June 2023
• Source: University Hospital, Strasbourg, France
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary purpose is to evaluate the impact of hypnosis coupled with MEOPA (Equimolar Mix-ture of Nitrogen Protoxide and Oxygen) on patient comfort when performing transoesophageal echocardiographies. Further studies on the use of MEOPA alone or the technique of hypnosis alone in the context of an TEE, would not be innovative in any way in view of previous studies or already in progress. However, service has led to perform TEEs several times by combining MEOPA and hypnosis. Doctors noted a clear reduction in induction time for hypnosis and satisfaction of the patient and operators. This association technique is very often used in pediatrics. According to one study, it seems that MEOPA increases the threshold of suggestibility and imagination. However suggestion and imagination are two essential notions of the hypnotic technique. To date, doctors have not found any other studies combining MEOPA and hypnosis for adults patients in the context of TEE. This leads to the following hypothesis: Is there a difference for the patient in terms of for the global management of pain and anxiety between an TEE performed under MEOPA with a standard support and TEE under MEOPA coupled with hypnosis with support standard? Secondary purposes are: 1. Compare patients' feelings / opinions: patients who have benefited from hypnosis associated with MEOPA versus patients who have been treated with MEOPA alone. 2. Compare patient stress: patients who have benefited from hypnosis associated with MEOPA versus patients who have benefited from MEOPA alone. 3. Compare the operators' feelings / opinions: procedures that have been performed under hypno-analgesia and MEOPA versus standard procedures under MEOPA alone. 4. Failed the TEE procedure

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 80
• Est. completion date: August 12, 2022
• Est. primary completion date: October 14, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient (male or female) of full age without upper age limit
• Patient hospitalized on the site of the Nouvel Hôpital Civil - Strasbourg, with an indication of transesophageal echography with a diagnostic purpose of a cardiac pathology (transesophageal echography scheduled the day after or the very day of selection)
• Patient affiliated to a social security health insurance scheme
• Patient able to understand the objectives and risks related to the research and to give an informed consent dated and signed
• For a woman of childbearing age: negative blood pregnancy test (test performed by the service as part of the care or diagnostic and therapeutic needs related to the patient's hospitalization).

Exclusion Criteria:

• Patient with a contraindication to the use of MEOPA
• Patient with little or no understanding of French
• Patient with hearing problems that do not allow hypnosis to occur
• Patient with psychiatric disorders (schizophrenia, psychosis, melancholic depression, hysteria...)
• Disoriented patients
• Patient receiving the following treatments/management:

ophthalmic gas centrally acting drugs: opiates, benzodiazepines and other psychotropic drugs (potentiation of effects).

• Long-term anxiolytics
• Premedications for transesophageal echocardiography by analgesics, Benzodiazepine, hydroxizine, antiemetics and gastric prokinetics or gabapentinoïdes (gabapentin, pregabaline)
• Psychocorporal therapies or complementary therapies during the period of hospitalization (psychotherapy, meditation, acupuncture...)
• Patient in exclusion period (determined by a previous or ongoing study),
• Impossibility of giving the patient informed information (patient in an emergency situation, difficulties in understanding, etc.)
• Pregnancy or breastfeeding reported by the patient
• Patients under curatorship, guardianship, protection of justice
• If the patient has an VAPS >8/10, the transesophageal echocardiography procedure and therefore its inclusion in the research will be postponed.

Related Conditions & MeSH terms

• Cardiac Diseases
• Heart Diseases

Intervention

Procedure:
• Transesophageal echography
Ultrasound examination of the heart using a soft tube. The extremity is inserted through the mouth and positioned in the esophagus behind the heart.

Locations

Country	Name	City	State
France	CHU Strasbourg - France	Strasbourg

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Strasbourg, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Concomitant Measure of Pain and Anxiety	Measurements are made according to self-evaluation scales	Change from baseline Concomitant Measure of Pain and Anxiety at 10 minutes transesophageal echography